| 产品描述: | SDZ 220-581 is an orally active, potent, competitive NMDA receptor antagonist with pKi value of 7.7 |
| 靶点: |
pKi: 7.7 (NMDA receptor);Others |
| 体内研究: |
SDZ 220-581 (3.2-32 mg/kg; oral administration; for 24 hours; male OF-l mice) treatment dose-dependently protects mice against maximal electroshock seizures (MES). The time-course of protection by SDZ 220-581 is characterized by a rapid onset and long duration of action |
| 参考文献: |
1. Urwyler S, Campbell E, Fricker G, Biphenyl-derivatives of 2-amino-7-phosphono-heptanoic acid, a novel class of potent competitive N-methyl-D-aspartate receptor antagonists--II. Pharmacological characterization in vivo. Neuropharmacology. 1996 Jun;35(6):65 2. Gilmour G, et al. In vitro characterisation of the novel positive allosteric modulators of the mGlu₅ receptor, LSN2463359 and LSN2814617, and their effects on sleep architecture and operant responding in the rat. Neuropharmacology. 2013 Jan;64:224-39. |
| 溶解性: |
Soluble in DMSO |
| 保存条件: |
2-8℃ |
| 配置溶液浓度参考: |
|
1mg |
5mg |
10mg |
| 1 mM |
2.705 ml |
13.523 ml |
27.046 ml |
| 5 mM |
0.541 ml |
2.705 ml |
5.409 ml |
| 10 mM |
0.27 ml |
1.352 ml |
2.705 ml |
| 50 mM |
0.054 ml |
0.27 ml |
0.541 ml |
|
| 注意: |
部分产品我司仅能提供部分信息,我司不保证所提供信息的权威性,仅供客户参考交流研究之用。 |